TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02477072

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEG
Description: Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEG
Description: Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle-brachial index
Description: Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ankle-brachial index
Description: Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toe-brachial index
Description: Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Toe-brachial index
Description: Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin doses will be administered according to the assigned group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin doses will be administered according to the assigned group.
Study: NCT01803828

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 20 mg/die (1 capsule)
Study: NCT02959866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online income tool
Description: An online tool that uses information about the patient to develop a tailored list of financial benefits that they are eligible to apply for.
Study: NCT02477072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Heparin doses will be administered according to the assigned group.
Study: NCT02477319

Intervention type: OTHER
Intervention: Observational

Intervention type: OTHER
Intervention: Observational
Study: NCT01280656

Intervention type: DRUG
Intervention: Conventional Interferon
Description: Conventional interferon according to the standard of care and aligned with the local prescription instructions

Intervention type: DRUG
Intervention: Peginterferon Alfa-2a
Description: Peginterferon alfa-2a according to the standard of care and aligned with the local prescription instructions

Intervention type: DRUG
Intervention: Peginterferon Alfa-2b
Description: Peginterferon alfa-2b according to the standard of care and aligned with the local prescription instructions

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin according to the standard of care and aligned with the local prescription instructions

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin according to the standard of care and aligned with the local prescription instructions

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin according to the standard of care and aligned with the local prescription instructions
Study: NCT02718456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expedited CD4 testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expedited CD4 testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supplemental peer counseling
Study: NCT02595788

Intervention type: OTHER
Intervention: Change from supine to prone position
Description: Change from supine to prone position
Study: NCT02885610

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus standard therapy
Description: Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 80 mg plus standard therapy
Description: Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 160 mg plus standard therapy
Description: Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 240 mg plus standard therapy
Description: Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
Study: NCT02416297

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation
Description: Flapless cortical perforations will be made 8 months minimum after dental extraction. Surgical protocol will be flapless to preserve periodontal health. After local anesthesia, 3 micro osteoperforations will be done with manual instrument, between apex to the contour of free gum between the canine and second pre-molar. Perforations near each tooth will have 6-8 mm depth
Study: NCT00038376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin (Accutane)
Description: 0.5 mg/k (1.0 mg/k total) by mouth twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alpha
Description: Starting dose of 3 MU injected under skin once a day for 12 weeks.
Study: NCT02558803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple Reminder
Description: A simple reminder prompt in which CHICA will provide an immunization reminder to the physician that the child is eligible for the 2nd or 3rd dose of vaccine.
Study: NCT04099186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter directed hydro-mechanical fragmentation of pulmonary embolism
Description: A(6)F multipurpose catheter will be advanced over a guide wire under fluoroscopic guidance and used to measure right heart and pulmonary artery pressures, then mechanical catheter fragmentation will be done using a pigtail catheter. The catheter will be quickly spun manually so as to fragment the central thrombus and establish initial flow into pulmonary artery , then 200 ml saline will be injected via power injector to aid fragmentation of thrombus
Study: NCT02649478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone / Salmeterol
Description: Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura LOMI inhaler device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advair Diskus 100/50
Description: Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
Study: NCT03803488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DropSafe safety pen needle
Study: NCT00596466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: pregabalin
Study: NCT04786327

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Minimal invasive flap technique
Description: contained defect treated with Minimally invasive flap
Study: NCT03543540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nexvax2
Description: Nexvax2 injections: 14 in total at twice weekly intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nexvax2
Description: Nexvax2 injections: 14 in total at twice weekly intervals

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections: 14 in total at twice weekly intervals

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections: 14 in total at twice weekly intervals
Study: NCT02097056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil HCL
Description: Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
Study: NCT04786327

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin
Description: contained defect treated by Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin graft

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21S
Description: contained defect treated with Minimally invasive flap with root conditioning (EDTA) and growth factor enhanced matrix application in the defect
Study: NCT04907201

Intervention type: PROCEDURE
Intervention: Cryoneurotomy
Description: Cryoneurotomy or application of a low temperature probe with guidance of ultrasound which is offered to the patients with lower limbs refractory spasticity as a part of their medical cares.
Study: NCT03906240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moral Elevation intervention
Description: The intervention will be administered twice per week for 8 sessions total. The intervention will include two types of moral elevation exercises related to witnessing virtuous behavior and subsequently setting session goals aimed to facilitate social engagement.
Study: NCT00731913

Intervention type: OTHER
Intervention: Absorable, monofilament sutures: Monosyn and Monocryl
Description: Subjects were randomized to Monosyn vs. Monocryl suture arms. The designated skin lesion was removed surgically. The surgical repair of the defect was performed by dividing the wound in half by a single Prolene suture. The appropriate suture was opened by the Study Coordinator and passed sterilely to the surgical technician. The surgical technician loaded the suture, and passed it in a blinded fashion to the physician who closed the appropriate half of the surgical defect. One half of the wound was closed with one suture and the other half was closed with the other suture. Each patient served as their own control, as both sutures were used in each study patient.

Intervention type: OTHER
Intervention: Absorable, monofilament sutures: Monosyn and Monocryl
Description: Subjects were randomized to Monosyn vs. Monocryl suture arms. The designated skin lesion was removed surgically. The surgical repair of the defect was performed by dividing the wound in half by a single Prolene suture. The appropriate suture was opened by the Study Coordinator and passed sterilely to the surgical technician. The surgical technician loaded the suture, and passed it in a blinded fashion to the physician who closed the appropriate half of the surgical defect. One half of the wound was closed with one suture and the other half was closed with the other suture. Each patient served as their own control, as both sutures were used in each study patient.
Study: NCT02648659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 10mg 1tablet qid(4 times/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 10mg 1tablet qid(4 times/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 10mg 1tablet qid(4 times/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 500mg 1capsule qid(4times/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 500mg 1capsule qid(4times/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 500mg 1capsule qid(4times/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin 500mg 1tablet bid(2times/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin 500mg 1tablet bid(2times/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 250mg 2tablets tid(3times/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 250mg 2tablets tid(3times/day)
Study: NCT03219788

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline will be given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil 0.1 ug/kg
Description: All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.1 ug/kg Remifentanil will be given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil 0.2 ug/kg
Description: All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.2 ug/kg Remifentanil will be given
Study: NCT03829371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Subcutaneous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Subcutaneous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral use
Study: NCT02185820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT00054821

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ankle distraction permitting motion
Description: External fixator is applied to ankle joint for 85 - 95 days; ankle motion is permitted

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle distraction without motion
Description: External fixator is applied to ankel joint for 85 - 95 days; ankle motion is not permitted
Study: NCT03152721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parkinson KinetiGraph
Description: The Parkinson Kinetigraph (PKG) is a wrist-worn accelerometer shaped as a watch. It records spontaneous movements and for every two minutes provides a bradykinesia score and a dyskinesia score. Furthermore it analysis movement for tremor-like episodes and registers the time with tremulous movements as well as time with extreme immobility suggesting sleep. The device can be programmed with drug intake times and provide a reminder signal. Intake of drug can be indicated on the device.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Self assessment
Description: Administration of self assessment questionnaires are made within 2 weeks from starting a PKG recording. The assessments are Parkinson Disease Quality of life 8 question short version and the Non Motor Symptom in Parkinson Disease Questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self assessment
Description: Administration of self assessment questionnaires are made within 2 weeks from starting a PKG recording. The assessments are Parkinson Disease Quality of life 8 question short version and the Non Motor Symptom in Parkinson Disease Questionnaire.
Study: NCT00953173

Intervention type: DEVICE
Intervention: LAP-BAND AP® Adjustable Gastric Banding System
Description: The LAP-BAND AP® is a device surgically implanted via a laparoscopic procedure. It is designed to induce weight loss in severely obese patients by limiting food consumption.
Study: NCT04156802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real TBS to the mPFC
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS to the mPFC
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real TBS to the MC
Description: This will be delivered with the Magventure Magpro system (double blinded).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS to the MC
Description: This will be delivered with the Magventure Magpro system (double blinded). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
Study: NCT02737410

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gut-directed Hypnotherapy
Description: The GHT protocol used was the Manchester protocol of GHT and consisted of 10 weekly sessions (45 min), with six patients per group over a treatment period of 12 weeks. GHT was performed at the University Hospital by two experienced physicians trained in Manchester (UK).
Study: NCT03644966

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis
Description: Probiotics

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic probiotic tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women
Study: NCT02822118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chang'an I Recipe
Description: Patients in this group were administered the Chang'an I Recipe, 150ml/bag, 3 times/day for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this group were administered the placebo, 150ml/bag, times/day for 8 weeks.
Study: NCT02784730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iterative PICC placement
Description: Intervention is the catheterisation strategy (not the device)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long term PAC placement
Description: Intervention is the catheterisation strategy (not the device)
Study: NCT03744208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-EGFR monoclonal antibody
Description: DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression
Study: NCT02711202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
Study: NCT00499005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntommetrine and Carbetocin
Description: Syntommetrine 1ml and Carbetocin 100microgram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntommetrine and Carbetocin
Description: Syntommetrine 1ml and Carbetocin 100microgram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntommetrine and Carbetocin
Description: Syntommetrine 1ml and Carbetocin 100micgrams

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntommetrine and Carbetocin
Description: Syntommetrine 1ml and Carbetocin 100micgrams
Study: NCT04089449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT811
Description: PRT811 will be administered orally
Study: NCT01002924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC145
Description: EC145 will be administered intravenously at a dose of 2.5 mg. Dosing will occur on Monday, Wednesday, and Friday of weeks 1 and 3 of each 4-week cycle. No therapy will be administered during weeks 2 and 4.
Study: NCT03829371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral use
Study: NCT04600947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP002
Description: 10 mg/kg administered as IV infusion on Day 1 of each 14-day cycle.
Study: NCT00036634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Description: Tenofovir alafenamide tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Description: Tenofovir alafenamide tablet(s) administered orally once daily
Study: NCT03636789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurological consultation
Description: study of horizontal, vertical, reflex and voluntary saccades, and of horizontal and vertical ocular pursuit by a BrainTracker eye-oculography system